CMMB News and Press, Chemomab Therapeutics Ltd.

—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— ...

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational Data Further Confirms CM-101’s ...

2024-05-09 11:57:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chemomab Therapeutics (NASDAQ: CMMB ) just reported results for the first quarter of 2024. Chemomab Therapeutics reported earnings per share of -28 cents. The company ...

2024-05-09 07:42:38 ET More on Chemomab Therapeutics Seeking Alpha’s Quant Rating on Chemomab Therapeutics Historical earnings data for Chemomab Therapeutics Financial information for Chemomab Therapeutics Read the full article on Seeking Alpha ...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule─ ─New Peer-Reviewed Publicat...

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the&#x...

A look at the top 10 most actives in the United States XBP Europe Holdings Inc. (XBP) rose 69.1% to $3.5846 on volume of 37,660,870 shares Lyra Therapeutics Inc. (LYRA) fell 90.2% to $0.3942 on volume of 21,985,500 shares NIO Inc. American depositary shares each representing one Class A (...

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will de...

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarte...